Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D62RIY
|
|||
| Drug Name |
VX-522
|
|||
| Drug Type |
mRNA therapy
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9] | Phase 1 | [1] | |
| Company |
Moderna
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | cAMP-dependent chloride channel (CFTR) | Target Info | . | [2] |
| KEGG Pathway | ABC transporters | |||
| cAMP signaling pathway | ||||
| AMPK signaling pathway | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Vibrio cholerae infection | ||||
| Reactome | ABC-family proteins mediated transport | |||
| WikiPathways | ABC-family proteins mediated transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05668741) A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Vertex | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.